ArticleCurrent fungal infection reports2019
Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.
Article in Current fungal infection reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07215273 (A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Cryptococcus: Emerging host risk factors for infection.PLoS pathogens · 2025Article
- Azole drugs have differential efficacy in varied models of immunosuppression in larval zebrafish hosts.Future microbiology · 2025Article
- Future Prospects and Challenges in Mucormycosis Research.Journal of fungi (Basel, Switzerland) · 2025Article
- Pulmonary Coccidioidomycosis Occurring in a Patient Treated With Acalabrutinib for Chronic Lymphocytic Leukemia.Cureus · 2025Article
- Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025Review
- Establishment and Validation of a UPLC-MS/MS Method for Quantitative Determination of Zanubrutinib and Posaconazole in Rat Plasma: Application in Drug-Drug Interaction Studies.Drug design, development and therapy · 2025Article
- Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort.Transplantation and cellular therapy · 2025Article
- Exploiting antifungal immunity in the clinical context.Seminars in immunology · 2023Review
- Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas.Cancers · 2023Review
- Immunity to fungi in the lung.Seminars in immunology · 2023Review
- Multiparametric Profiling of Neutrophil Function via a High-Throughput Flow Cytometry-Based Assay.Cells · 2023Article
- Pathogenesis and virulence ofVirulence · 2022Review
- Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- TLR Signaling Rescues Fungicidal Activity in Syk-Deficient Neutrophils.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Case Commentary: Long-Term Fosmanogepix Use in a Transplant Recipient with Disseminated Aspergillosis Caused by Azole-Resistant Aspergillus calidoustus.Antimicrobial agents and chemotherapy · 2022Article
- Review
- Systemic Aspergillosis: Radiological Findings in a Case With Diffuse Large B Cell Lymphoma Treated by Ibrutinib.Cureus · 2021Article
- Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib.BMJ case reports · 2021Article
- Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.Cancers · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
purpose of reviewSmall molecule kinase inhibitors (SMKIs) have revolutionized the management of malignant and autoimmune disorders. Emerging clinical reports point toward an increased risk for invasive fungal infections (IFIs) in patients treated with certain SMKIs. In this mini-review, we highlight representative examples of SMKIs that have been associated with or are expected to give rise to IFIs. RECENT
findingsThe clinical use of the Bruton's tyrosine kinase inhibitor ibrutinib as well as other FDA-approved SMKIs has been associated with IFIs. The fungal infection susceptibility associated with the clinical use of certain SMKIs underscores their detrimental effects on innate and adaptive antifungal immune responses. SUMMARY: The unprecedented development and clinical use of SMKIs is expected to give rise to an expansion of iatrogenic immunosuppressive factors predisposing to IFIs (and other opportunistic infections). Beyond increased clinical surveillance, better understanding of the pathogenesis of SMKI-associated immune dysregulation should help devising improved risk stratification and prophylaxis strategies in vulnerable patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.